DEMEROL 100 MG/ML SOLUTION

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

MEPERIDINE HYDROCHLORIDE

Предлага се от:

HOSPIRA HEALTHCARE ULC

АТС код:

N02AB02

INN (Международно Name):

PETHIDINE

дозиране:

100MG

Лекарствена форма:

SOLUTION

Композиция:

MEPERIDINE HYDROCHLORIDE 100MG

Начин на приложение:

INTRAMUSCULAR

Броя в опаковка:

20ML

Вид предписание :

Narcotic (CDSA I)

Терапевтична област:

OPIATE AGONISTS

Каталог на резюме:

Active ingredient group (AIG) number: 0104542004; AHFS:

Статус Оторизация:

CANCELLED POST MARKET

Дата Оторизация:

2018-10-25

Данни за продукта

_N_
_DEMEROL _
_Page 1 of 33 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
DEMEROL
(MEPERIDINE HYDROCHLORIDE INJECTION USP)
50 mg/mL, 75 mg/mL and 100 mg/mL
Sterile Solution
NARCOTIC ANALGESIC
Hospira Healthcare Corporation
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Date of Revision:
April 26, 2018
Submission Control No: 212492
_N_
_DEMEROL _
_Page 2 of 33 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................22
SPECIAL HANDLING INSTRUCTIONS
.......................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................23
PART II: SCIENTIFIC INFORMATION
...............................................................................24
PHARMACEUTICAL INFORMATION
..........................................................................24
PATIENT MEDI